Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.280
-0.090 (-6.57%)
At close: Jun 5, 2026, 4:00 PM EDT
1.330
+0.050 (3.90%)
After-hours: Jun 5, 2026, 7:56 PM EDT
Ocugen Revenue
Ocugen had revenue of $1.53M in the quarter ending March 31, 2026, with 3.51% growth. This brings the company's revenue in the last twelve months to $4.47M, down -1.26% year-over-year. In the year 2025, Ocugen had annual revenue of $4.41M with 8.83% growth.
Revenue (ttm)
$4.47M
Revenue Growth
-1.26%
P/S Ratio
97.05
Revenue / Employee
$38,491
Employees
116
Market Cap
433.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.41M | 358.00K | 8.83% |
| Dec 31, 2024 | 4.06M | -1.98M | -32.82% |
| Dec 31, 2023 | 6.04M | 3.55M | 142.60% |
| Dec 31, 2022 | 2.49M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 43.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 8.00K | -18.00K | -69.23% |
| Dec 31, 2012 | 26.00K | -97.00K | -78.86% |
| Dec 31, 2011 | 123.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sutro Biopharma | 99.61M |
| 4D Molecular Therapeutics | 88.24M |
| Editas Medicine | 38.69M |
| C4 Therapeutics | 34.86M |
| Ovid Therapeutics | 7.12M |
| Neurogene | 925.00K |
OCGN News
- 1 day ago - Ocugen Transcript: Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference - Transcripts
- 3 days ago - Ocugen to Participate in Upcoming June Investor and Industry Conferences - GlobeNewsWire
- 9 days ago - Ocugen price target lowered to $11 from $12 at Canaccord - TheFly
- 10 days ago - Ocugen Transcript: Stifel 2026 Virtual Ophthalmology Forum - Transcripts
- 22 days ago - Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes - GlobeNewsWire
- 23 days ago - Ocugen to Participate in Upcoming May Scientific and Investor Conferences - GlobeNewsWire
- 4 weeks ago - Ocugen reports Q1 EPS (6c), consensus (5c) - TheFly
- 4 weeks ago - Ocugen Provides Business Update with First Quarter 2026 Financial Results - GlobeNewsWire